Bioventus Inc. (NASDAQ: BVS) reported Q4 EPS of $0.07, $0.05 better than the analyst estimate of $0.02. Revenue for the quarter came in at $135.42 million versus the consensus estimate of $123.96 million.

GUIDANCE:

Bioventus Inc. sees FY2024 EPS of $0.12-$0.20, versus the consensus of $0.33. Bioventus Inc. sees FY2024 revenue of $520-535 million, versus the consensus of $517.7 million.

For earnings history and earnings-related data on Bioventus Inc. (BVS) click here.